Literature DB >> 15864586

Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer?

B M Reipert1, S Tanneberger, A Pannetta, M Bedosti, M Poell, K Zimmermann, M T Stellamor.   

Abstract

A thorough understanding of the naturally occurring events in the immune system in response to carcinogenesis will facilitate the development of strategies for the immunoprevention of cancer. The adenoma-carcinoma sequence in the human colon is a well-established clinical example of multi-step carcinogenesis and can be used for immunological studies. Based on previous observations that both apoptosis and the expression of Fas (Apo-1, CD95) are altered during carcinogenesis in the human colon, we asked the question whether serum titers of autoantibodies against Fas show any modification during the adenoma-carcinoma sequence. Healthy controls (38), patients with colorectal adenomas (38) and patients with colorectal adenocarcinomas (21) were investigated. Anti-Fas antibody titers were found to be significantly higher in patients with colorectal adenomas than in healthy controls and higher still in patients with colorectal adenocarcinomas. This increase in anti-Fas autoantibody titers during carcinogenesis might reflect the activation of natural defense mechanisms by the immune system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864586     DOI: 10.1007/s00262-005-0679-0

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  6 in total

Review 1.  Do antiphospholipid antibodies develop for a purpose?

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 2.  Blood-based tests for colorectal cancer screening: do they threaten the survival of the FIT test?

Authors:  Robert S Bresalier; Scott Kopetz; Dean E Brenner
Journal:  Dig Dis Sci       Date:  2015-02-14       Impact factor: 3.199

Review 3.  Usage of cancer associated autoantibodies in the detection of disease.

Authors:  Steven P Dudas; Madhumita Chatterjee; Michael A Tainsky
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

4.  The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.

Authors:  Ramazan Yildiz; Mustafa Benekli; Suleyman Buyukberber; Ali Osman Kaya; Banu Ozturk; Emel Yaman; Veli Berk; Ugur Coskun; Deniz Yamac; Banu Sancak; Aytug Uner
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-13       Impact factor: 4.553

5.  Potential of soluble CD26 as a serum marker for colorectal cancer detection.

Authors:  Oscar J Cordero; Monica Imbernon; Loretta De Chiara; Vicenta S Martinez-Zorzano; Daniel Ayude; Maria Paez de la Cadena; F Javier Rodriguez-Berrocal
Journal:  World J Clin Oncol       Date:  2011-06-10

6.  Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays.

Authors:  Ingrid Babel; Rodrigo Barderas; Ramón Díaz-Uriarte; Jorge Luis Martínez-Torrecuadrada; Marta Sánchez-Carbayo; J Ignacio Casal
Journal:  Mol Cell Proteomics       Date:  2009-07-28       Impact factor: 5.911

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.